Literature DB >> 28218604

Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions.

Jiang Ming Fam1, Soledad Ojeda, Roberto Garbo, Azeem Latib, Alessio La Manna, Beatriz Vaquerizo, Marouane Boukhris, Georgios J Vlachojannis, Robert-Jan van Geuns, Babu Ezhumalai, Hiroyoshi Kawamoto, Jors van der Sijde, Cordula Felix, Manuel Pan, Roberta Serdoz, Giacomo Giovanni Boccuzzi, Marcella De Paolis, Gennaro Sardella, Massimo Mancone, Corrado Tamburino, Pieter C Smits, Carlo Di Mario, Ashok Seth, Antonio Serra, Antonio Colombo, Patrick Serruys, Alfredo R Galassi, Felix Zijlstra, Nicolas M Van Mieghem, Roberto Diletti.   

Abstract

AIMS: Bioresorbable vascular scaffolds (BVS) represent a novel therapeutic option for the treatment of coronary artery diseases. The objective of this study was to evaluate the feasibility of BVS implantation in complex chronic total occlusions (CTO). METHODS AND
RESULTS: The present report is a multicentre registry evaluating results after BVS deployment in challenging CTO lesions, defined as J-CTO score ≥2 (difficult or very difficult). A total of 105 patients were included in the present analysis. The mean J-CTO score was 2.61 (difficult 52.4%, very difficult 47.6%). Device success and procedural success rates were 98.1% and 97.1%, respectively. The retrograde approach was used in 25.7% of cases. After wire crossing, predilatation was performed in all cases with a mean predilatation balloon diameter of 2.73±0.43 mm. The mean scaffold length was 59.75±25.85 mm, with post-dilatation performed in 89.5% of the cases and a mean post-dilatation balloon diameter of 3.35±0.44 mm. Post-PCI minimal lumen diameter was 2.50±0.51 mm and percentage diameter stenosis 14.53±10.31%. At six-month follow-up, a total of three events were reported: one periprocedural myocardial infarction, one late scaffold thrombosis and one additional target lesion revascularisation.
CONCLUSIONS: The present report suggests the feasibility of BVS implantation in complex CTO lesions, given adequate lesion preparation and post-dilatation, with good acute angiographic results and midterm clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28218604     DOI: 10.4244/EIJ-D-16-00253

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  4 in total

1.  Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions : 2017 revision.

Authors:  B Everaert; J J Wykrzykowska; J Koolen; P van der Harst; P den Heijer; J P Henriques; R van der Schaaf; B de Smet; S H Hofma; R Diletti; A Weevers; J Hoorntje; P Smits; R J van Geuns
Journal:  Neth Heart J       Date:  2017-07       Impact factor: 2.380

Review 2.  Clinical Outcomes of Successful Revascularization of Chronic Total Coronary Occlusions with Bioresorbable Vascular Scaffolds: A Systematic Review.

Authors:  Roman Marchenko; Salik Nazir; Shelina Malla; Anthony Donato
Journal:  Cureus       Date:  2018-11-28

3.  Bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: a meta-analysis.

Authors:  Alberto Polimeni; Remzi Anadol; Thomas Münzel; Martin Geyer; Salvatore De Rosa; Ciro Indolfi; Tommaso Gori
Journal:  BMC Cardiovasc Disord       Date:  2019-03-15       Impact factor: 2.298

Review 4.  Bioresorbable Vascular Scaffolds-Dead End or Still a Rough Diamond?

Authors:  Mateusz P Jeżewski; Michał J Kubisa; Ceren Eyileten; Salvatore De Rosa; Günter Christ; Maciej Lesiak; Ciro Indolfi; Aurel Toma; Jolanta M Siller-Matula; Marek Postuła
Journal:  J Clin Med       Date:  2019-12-07       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.